Musa Fares Alzahrani, Thamer Basahih, Ghazi Alotaibi, Sarah Sewaralthahab, Fatimah Alshalati, Ibrahim Alrumaih, Kazi Nur Asfina, Ahmed Gamal, Farjah Algahtani, Aamer Aleem
{"title":"Survival and Outcome of Patients with Diffuse Large B-cell Lymphoma According to the Central Nervous System-International Prognostic Index.","authors":"Musa Fares Alzahrani, Thamer Basahih, Ghazi Alotaibi, Sarah Sewaralthahab, Fatimah Alshalati, Ibrahim Alrumaih, Kazi Nur Asfina, Ahmed Gamal, Farjah Algahtani, Aamer Aleem","doi":"10.4103/sjmms.sjmms_654_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that estimates the risk of progression to the central nervous system (CNS-IPI) was published. Whether the CNS-IPI index is sufficient to prognosticate DLBCL survival is yet untested.</p><p><strong>Objectives: </strong>We aim to describe the outcomes of DLBCL patients based on CNS-IPI risk groups.</p><p><strong>Methods: </strong>We retrospectively reviewed all DLBCL cases diagnosed from January 2015 until April 2022 at an academic tertiary hospital in Riyadh, Saudi Arabia. CNS-IPI was calculated at the time of diagnosis. The outcomes were compared between two CNS-IPI risk categories: low and intermediate/high-risk groups. Logrank method was used to calculate <i>P</i> value, and Kaplan-Meier method to estimate survival.</p><p><strong>Results: </strong>A total of 136 patients were included (median age: 56.5 years), of which 38 (28%) died: 5 in the low-risk group and 33 in the intermediate/high-risk group. Low-risk and intermediate/high-risk CNS-IPI were found in 41 (30%) and 95 (70%) patients, respectively. The median survival in the low-risk and intermediate/high-risk CNS-IPI groups was 66 months [95% CI: 60-not-reached (NR)] and NR (95% CI: 24-NR) (<i>P</i> = 0.007), respectively. Only seven (5%) patients developed progression to the CNS, of which 6 (86%) were in the intermediate/high-risk group.</p><p><strong>Conclusion: </strong>The risk of progression to the central nervous system was moderate in our diffuse large B-cell lymphoma population. Patients with intermediate/high-risk CNS-IPI had worse survival compared with low-risk patients. The CNS-IPI was found to a good model to not only estimate the risk of disease progression to the central nervous system but also overall survival.</p>","PeriodicalId":21442,"journal":{"name":"Saudi Journal of Medicine & Medical Sciences","volume":"13 3","pages":"205-209"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medicine & Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjmms.sjmms_654_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Several prognostic scores exist in DLBCL, including the International Prognostic Index (IPI). More recently, a modification of the IPI that estimates the risk of progression to the central nervous system (CNS-IPI) was published. Whether the CNS-IPI index is sufficient to prognosticate DLBCL survival is yet untested.
Objectives: We aim to describe the outcomes of DLBCL patients based on CNS-IPI risk groups.
Methods: We retrospectively reviewed all DLBCL cases diagnosed from January 2015 until April 2022 at an academic tertiary hospital in Riyadh, Saudi Arabia. CNS-IPI was calculated at the time of diagnosis. The outcomes were compared between two CNS-IPI risk categories: low and intermediate/high-risk groups. Logrank method was used to calculate P value, and Kaplan-Meier method to estimate survival.
Results: A total of 136 patients were included (median age: 56.5 years), of which 38 (28%) died: 5 in the low-risk group and 33 in the intermediate/high-risk group. Low-risk and intermediate/high-risk CNS-IPI were found in 41 (30%) and 95 (70%) patients, respectively. The median survival in the low-risk and intermediate/high-risk CNS-IPI groups was 66 months [95% CI: 60-not-reached (NR)] and NR (95% CI: 24-NR) (P = 0.007), respectively. Only seven (5%) patients developed progression to the CNS, of which 6 (86%) were in the intermediate/high-risk group.
Conclusion: The risk of progression to the central nervous system was moderate in our diffuse large B-cell lymphoma population. Patients with intermediate/high-risk CNS-IPI had worse survival compared with low-risk patients. The CNS-IPI was found to a good model to not only estimate the risk of disease progression to the central nervous system but also overall survival.
期刊介绍:
Saudi Journal of Medicine & Medical Sciences (SJMMS) is the official scientific journal of Imam Abdulrahman Bin Faisal University. It is an international peer-reviewed, general medical journal. The scope of the Journal is to publish research that will be of interest to health specialties both in academic and clinical practice. The Journal aims at disseminating high-powered research results with the objective of turning research into knowledge. It seeks to promote scholarly publishing in medicine and medical sciences. The Journal is published in print and online. The target readers of the Journal include all medical and health professionals in the health cluster such as in medicine, dentistry, nursing, applied medical sciences, clinical pharmacology, public health, etc.